Breast Cancer

Sara Hurvitz MD FACP and Kathy D. Miller MD review and share their expert perspectives on key breast cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Share

Program Content

Activities

  • Pembro in mTNBC
    KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2017

    Expires: June 03, 2018

  • Ipatasertib + Pac in TNBC
    LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2017

    Expires: June 03, 2018

  • APHINITY: Pertuzumab in HER2+ EBC
    APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2017

    Expires: June 04, 2018

  • Dual HER2 Blockade + AI in MBC
    ALTERNATIVE: Dual HER2 Blockade + Aromatase Inhibitor in Postmenopausal Women With HER2+, HR+ MBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2017

    Expires: June 05, 2018

  • Carboplatin, Veliparib in Early TNBC
    Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2017

    Expires: June 06, 2018

  • MONARCH 2
    MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2017

    Expires: June 06, 2018

  • Olaparib in HER2-, <i>gBRCA</i>m MBC
    OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, BRCA-Mutated MBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2017

    Expires: June 07, 2018

  • SOLE: Letrozole Frequency
    Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2017

    Expires: June 07, 2018

  • I-SPY 2: Pembrolizumab in EBC
    I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2017

    Expires: June 08, 2018

  • PlanB: TC vs EC-T in HER2- EBC
    Phase III PlanB Final Analysis: Adjuvant TC vs EC→T in Pts With High-Risk HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2017

    Expires: June 11, 2018

  • TRAIN-2: Neoadjuvant CT ± Anthracyclines in HER2+ EBC
    TRAIN-2 (BOOG 2012-03): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology